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ABSTRACTSClinicopathologic factors including ER and Her2/neu receptor status are
associated with response to neoadjuvant chemotherapy. The Neoadjuvant
nomogrammay be a useful tool in our population of breast cancer patients.
0920: BREAST RADIO-GUIDED OCCULT LESION LOCALISATION (ROLL):
A GOOD ALTERNATIVE TO WIRE-GUIDED LOCALISATION
Han-Sian Lee, Syeda Gilani, Noaman Sarfraz. Warrington & Halton NHS
Hospitals Trust, Merseyside, UK
Aim: To assess the emerging role of radio-guided occult lesion localisation
(ROLL) as a superior alternative to conventional wire-guided localisation
methods in the removal of impalpable breast lesions. This project assessed
the excision margins and re-excision rates of ROLL and compared them to
NICE-based wide local excision (WLE) standards.
Method: Data was collected on a retrospective basis for all patients who
underwent the ROLL-guided removal of screen-detected and incidental
non-palpable breast cancers from July 2009 to July 2011. Benign tumours
and lymphoma(s) excised using ROLL were excluded.
Results: A total of 76 cases were examined. The re-excision rates using the
ROLL technique with a < 2 mm excision margin stood at 7 cases (9.2%)
overall, but this included 4 patients (5.2%) with multi-focal disease
undergoing mastectomy. Only 3 patients (3.9%) required further WLE as
the only procedure. This is well below the NICE guidelines of re-excision
rates for WLE of 13 - 19% of similar margins.
57% of patients had the tumour size up-scaled from the ultrasonic
measurement on ﬁnal histology.
Conclusion: The ROLL technique for the management of non-palpable
breast lesions does effectively show better results as compared to wire-
guided procedures. Further research is necessary to establish the exact role
of ROLL.
0981: WHEN SHOULD WE CONSIDER CONTRALATERAL PROPHYLACTIC
MASTECTOMY IN BRCA1/BRCA2 NEGATIVE FAMILIAL BREAST CANCER
PATIENTS? A STUDY OF HISTOPATHOLOGICAL PATTERNS
Fatima Aloraiﬁ, Trudi McDevitt, Nuala Cody, Marie Meany, Cliona de
Baroid, Rosemarie Kelly, Adrian Bracken, Andrew Green, James
Geraghty. National Centre for Medical Genetics, Dublin, Ireland
Aims: Little is known on the management of BRCA1/BRCA2-negative
familial breast cancer. This study aims to characterize histopathological
data on these patients in order to help in predicting the likelihood of
contralateral breast cancer.
Methods: A 5-year retrospective study was performed on patients referred
to the National Centre for Medical Genetics in Ireland from 2007-2011 for
genetic testing. Clinical and histopathological reports were collected from
high-risk patients (Manchester score >¼16) negative to BRCA1/BRCA2
(N¼179).
Results:42/179 (23%) high-riskBRCA1/BRCA2-negative patients hadbilateral
breast cancer. 22/42 (52%) were moderate to high grade, 20/42 (47%) were
ER+, 6/42 (14%) were HER2+ and 4/42 (10%) were triple negative. Interest-
ingly, only 7/42 (16%) of these tumours were lobular carcinoma.
Conclusion: BRCA1/BRCA2-positive breast cancer patients are considered
high-risk and offered bilateral prophylactic mastectomies. However, these
patients only account for a small proportion of familial breast cancer.
Despite intensive efforts, the discovery of additional breast cancer pre-
disposing genes to account for the large proportion of familial breast
cancer has so far been unsuccessful. Therefore, efforts should be made to
create a scoring system to predict the likelihood of bilateral breast cancer
in this patient group through histopathological data in a larger scale
multinational study.
0992: COULD A PROPORTION OF FAMILIAL BREAST CANCER PATIENTS
TESTING NEGATIVE TO BRCA1 AND BRCA2 IN FACT BE FALSE
NEGATIVES IN THE REPUBLIC OF IRELAND?
Fatima Aloraiﬁ, Trudi McDevitt, Nuala Cody, Marie Meanie, Cliona de
Baroid, Rosemarie Kelly, Adrian Bracken, Andrew Green, James
Geraghty. National Centre for Medical Genetics, Dublin, Ireland
Aim: The National Centre for Medical Genetics (NCMG) provides genetic
testing for familial breast cancer patients throughout Ireland. We per-
formed an audit of BRCA1/BRCA2-negative familial breast cancer patients
and assessed their characteristics.Methods: BRCA1/BRCA2 genetic testing data was collected prospectively
since the NCMG service was ﬁrst introduced in 1998 to present. In addi-
tion, we collected histopathological data on patients from 2007 to 2011
and performed a literature review on BRCA1/BRCA2-positive breast cancer
histological data from previous international reports to compare it with
our Irish cohort.
Results: Since 1998, 618 high-risk affected breast cancer patients were
referred to the NCMG. Only 16% tested positive for BRCA1/BRCA2 germline
mutations. According to the literature, BRCA1-positive tumours tend to be
triple negative and of high grade. In 179 affected patients negative to
BRCA1/BRCA2, 26/179 (15%) were triple negative, 41/179 (23%) were high
grade and 10/179 (6%) were both.
Conclusion: International statistics show that the susceptibility genes
BRCA1 and BRCA2 comprise 25% of familial breast cancer. However, in
Ireland, we show that only 16% are tested positive for BRCA1/BRCA2
mutations at the NCMG. Our next step will be to perform next generation
DNA sequencing on invited participants in order to address this clinically
important question.
1018: ROLE OF MRI IN INVASIVE BREAST CANCER
D. Oweis, P. Rushton, V. Kurup. North Tees and Hartlepool NHS Foundation
Trust, Stockton, UK
Aim: To study the effect of preoperative breast MRI on change of surgical
management in invasive breast cancers.
Methods: Retrospective study of patients(pts) with invasive breast cancer
who underwent a preoperative breast MRI between Jan ‘09 and Dec’11.
Data collected included demographics, radiological investigations, surgical
treatment &histology.
Results: 79pts. with a mean age of 58.6years were included. 24 pts.
underwent breast conservative surgery, 55 pts. had mastectomy. Mean
histological tumour size was 32.5mm. There was a signiﬁcant difference
between MRI size of tumour (mean 36.5mm) and the histological size
(mean 31.3mm) (p¼ 0.19). A signiﬁcant difference was found between the
mammogram(MMG)/Ultrasound(US) size (mean 19.7mm) and the MRI
size (mean 34.5mm). 31.2% had 2cm discrepancy between MMG/US and
MRI and 56.2% had 1cm, 29.2% were multifocal. Discrepancy of 2cm
between MRI and histology was seen in 19.2% and 1cm in 24.4%, 55.9%
were multifocal.
31pts (39.2%) had a change in the operative plan because of a new ipsi-
lateral multifocality (16pts.), contralateral cancer (1pt) or larger cancer
(12pts). Two pts had both a new multifocality and a contralateral breast
cancer. 84% of those had lobular breast cancer.
Conclusion: MRI plays a major role in detecting additional cancer-
s/bigger size and in planning course of treatment especially in lobular
cancers.
1052: WHAT IS THE COST-EFFECTIVENESS FOR MAMMOGRAMS FOR
DETECTING BREAST CANCER RECURRENCE COMPARED WITH THOSE
FOR BREAST CANCER SCREENING?
Lydia Gabriel, Ellena Smith, Sunreet Randhawa, Katy Hogben. Imperial
College NHS Trust, London, UK
Background: There are limited NICE guidelines regarding follow-up
after breast cancer surgery. At Charing Cross, London patients are fol-
lowed up with yearly clinical and mammographic assessment for
5years. The aim of this audit is to determine if annual mammographic
follow-up for breast cancer is cost effective compared to screening
mammography.
Methods: A retrospective audit, for breast patients cancer undergoing
surgery during 2005 at Charing Cross Hospital, London. Data collected
included operative procedures performed, length of follow-up, and
recurrence (method of detection for recurrence) and survival rates. Data
was compared to the pick-up rate NHS Breast Screening Pro-
gramme(NHSBCSP) Audit2008-2009.
Results: 269patients underwent surgery from January-December 2005,
full data collection was possible on 213patients. Average follow up was
4.68years, which equates to 996mammograms(£34860). During this time
there have been 25deaths and 28recurrences. Of the recurrences, 5were
detected by follow up mammogram only. The NHSBCSP detected 17,045
cancers from2008-2009. 199 follow-up mammograms(costing £6965)
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ABSTRACTSwere required to detect one cancer, while 124 screening mammog-
rams(costing £4340) were required to detect one cancer.
Conclusions: Routine annual mammograms for breast cancer recurrence
are less cost effective than those for the NHSBCSP. Stratiﬁed follow up or
less frequent mammograms should be considered for detecting recur-
rence.
1057: DO YOUNG WOMEN WITH CLINICALLY AND RADIOLOGICALLY
BENIGN BREAST LUMPS REQUIRE BIOPSIES?
Deepak Vijayan, Kolitha Goonetilleke, Kiren Virdee, Nikhal Sharma, Martin
Sintler. Sandwell General Hospital, Birmingham, UK
Aim: Women <25 years with clinically and radiologically benign breast
lumps do not require a biopsy in accordance with RCR guideline 2010.
Methods: A retrospective audit of all women under 30 years having
a breast biopsy at SWBH NHS Trust between Jan 2000 and Dec 2010.
Clinical, radiological and histological data were compared.
Results: 864 patients were identiﬁed from the pathology database, 612
had FNAC and 252 had core biopsy. 544 patients had full data sets available
for analysis. 91.2% (496) were p2 u2, all were conﬁrmed b2 histology. 7.2%
(39) were p2+ u3 with histology downgrading all of them to b2. 1.7% (9)
were p3+ u3+ and histology graded them as b4+. 61.4% (334) of the dataset
< 25years old. 10 cancers were detected, 1 <25 yrs (P2 U2), 9 >25yrs all
suspicious clinically and radiologically.
Conclusions: 91.2% of biopsies could have been avoided. Clinical and
Radiological ﬁndings show a high correlation < 30 years. Only 0.18% (1)
showed a discrepancy from the guidelines. 8.8% of the patients would
have required biopsies in keeping with the guidelines; a substantial
saving in psychological stress to patients, ﬁnancial cost and manpower
time.
1071: IMPROVING THE SERVICE FOR PATIENTS WITH BENIGN BREAST
BIOPSY RESULTS: LESSONS LEARNT FROM A BUSY DISTRICT GENERAL
HOSPITAL
Richard Boulton 1, Shanjitha Kantharuban 2, Ruth James 2, Kian
Chin 2, Amanda Taylor 2. 1North Middlesex University Hospital, London, UK,;
2Milton Keynes Foundation Hospital, Milton Keynes, Buckinghamshire, UK
Aims: In 2005 the NHS Breast Screening Programme published guidelines
recommending that 90% of breast biopsy results should be given to
patients within a week.
We set up a Consultant-led telephone biopsy results service in response to
a recent questionnaire study that demonstrated 77% of our patients did not
want a follow up appointment if their biopsy result was benign. Our
experience and audit results are presented below.
Methods: Retrospective analysis of 25 under 35 year clinic patients with
benign histology between August 2009 and February 2010, and prospec-
tive analysis of 35 patients identiﬁed as suitable for telephone results in
July 2010.
Results: Between August 2009 and February 2010 the average wait from
appointment to the patient receiving benign biopsy results were 25 days
(16-61). 0% of patients were informed within a week. The average wait for
results via telephone call was 6 days (2-12), with 88% (31/35) receiving
results in 7 days or less.
Conclusions: There was a signiﬁcant reduction in patient wait for benign
histology results after the introduction of a Consultant-led telephone
service, which approached the NHSBSP target of 90%. This has reduced
patient anxiety, clinic attendances and net departmental workload with
resultant ﬁnancial savings.
1077: AN ANALYSIS OF EMERGENCY ADMISSIONS RELATED TO PRIMARY
BREAST SEPSIS: A THREE-YEAR STUDY
George Kerans, Zoe Lin, Debasish Debnath, Lorna Cook, Isabella
Karat, Raouf Daoud, Ian Laidlaw. Frimley Park Hospital, Frimley, Surrey, UK
Aim: Factors related to emergency admission of primary breast sepsis are
not well known. We aimed to evaluate any such underlying factors.
Method: Analysis of all emergency breast-related emergency admissions
from 1st January 2009 to 31st December 2011 was performed retrospec-
tively. Statistical analysis was performed using SPSS 16.0.
Results: Some 140 breast-related emergency admissions took place over
a three year period. A total of 89 admissions (59.7%) were due to primarybreast sepsis (either cellulites or abscess, unrelated to any recent breast
intervention). Patients with primary breast sepsis were signiﬁcantly
younger (40.916.1 years), compared to those who were admitted with
other breast emergencies (such as haematoma, postoperative wound
infection, pain, seroma, etc.) (53.415.0 years) [p<0.001]. Monthly
occurrence of primary breast sepsis was highest in July (n¼14) and lowest
in September (n¼3) [p¼0.06]. Seasonal occurrences of primary breast
sepsis were as follows- winter (18), spring (20); summer (29) and autumn
(22) [p¼0.29].
Conclusions: Incidence of primary breast abscess requiring emergency
admission remained moderate and peaked in July and summer. Patients
with primary breast sepsis were signiﬁcantly younger than those without.
These may improve our current understanding and have implications on
service provision.
1079: AN AUDIT OF PRE-OPERATIVE AXILLARY ULTRASOUND
ASSESSMENT IN BREAST CANCER
Matthew Green, Ani Tencheva, Hemant Ingle, Jamie McIntosh. Good Hope
Hospital, Sutton Coldﬁeld, UK
Aim: To assess the sensitivity and speciﬁcity of pre-operative axillary
ultrasound in predicting lymph node metastases in breast cancer.
Method: A retrospective review of patients undergoing surgery for breast
cancer over a 12-month study period was undertaken. Data was collected
on pre-operative lymph node radiology, cytology and histopathology and
correlated with post-operative histological nodal status.
Out of 93 patients, 31 had radiologically abnormal axillary ultrasound
scans (group 1) whilst 62 were normal (group 2).
In group 1- 2 patients underwent ultrasound-guided biopsy of node, 3
underwent sentinel lymph node biopsy (SLNB), 28 underwent primary
axillary node clearance (ANC) and 1 underwent secondary ANC (following
SLNB).
In group 2- 47 underwent SLNB, 15 underwent primary ANC and 11
underwent secondary ANC
Results: In group 1, 87% of patients had involved nodes comparedwith 39%
of patients in group 2. This data gives the sensitivity of ultrasound scan of
the axilla as 52.9%, a speciﬁcity of 90.5%, positive predictive value of 87.1%
and a negative predictive value of 61.3%.
Conclusions: Isolated ultrasound assessment of axillary lymph nodes has
an unacceptably low sensitivity, although speciﬁcity is high. Sensitivity
may be improved by combining pre-operative imaging with guided lymph
node biopsies.
1093: INVESTIGATING THE IMPACT OF NEOADJUVANT CHEMOTHERAPY
AND HERCEPTIN ON THE SURGICAL MANAGEMENT OF PATIENTS WITH
INVASIVE BREAST CANCER
Terri McVeigh, Dhaﬁr Al-Azawi, Karl Sweeney, Carmel Malone, Maccon
Keane, Ray McLaughlin, Michael Kerin. Galway University Hospital,
Galway, Ireland
Aims: Neoadjuvant Chemotherapy(NCT) is indicated in locally aggressive
invasive breast cancers. The aims of this study are to audit the surgical
management of patients managed with NCT, including Herceptin, in
a tertiary referral centre in the west of Ireland, and to assess the impact of
receptor status on response to chemotherapy.
Methods: The cohort studied included all patients assigned to NCT
between 1999-2010. Data regarding patient demographics, tumour char-
acteristics, nodal management, ﬁnal pathological score and outcome was
obtained from a prospectively maintained database. Analysis was
completed using PASWv18.
Results: 152 patients were assigned to NCT including 5 with bilateral
disease. Following chemotherapy, 140 patients underwent Axillary Clear-
ance(AXCn), of which 53 were negative. NCT was found to be effective in
77.9% of patients, 29.3% having a complete pathological response, and
a further 48.6% having partial response. Breast Conservationwas facilitated
in 42 patients(28.57%). Luminal-A subtypewas themolecular subtypemost
often associated with a poor response (30.14%), while all those positive for
Her-2 receptor had at least a partial response, 50% a complete response.
Conclusion: AXCn in this cohort remains controversial, with 38% of
patients assigned to AXCn with no additional positive lymph node yield.
Those patients treated with chemotherapy targeting Her2-receptor had
a better response than Her2-negative patients.
